Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Lakewood-Amedex Biotherapeutics Inc.

Ticker
LABT
Sector
Industry
Report date
November 16, 2026
Valye AI Score

57

Moderate visibility
Recent developments
Recent developments summary

Recent developments highlight Lakewood-Amedex's clinical progress with Nu-3, regulatory approvals, stock market activity, and financial disclosures.

Recent developments:
  • Lakewood-Amedex secured IRB approval to begin a Phase 2a clinical study of Nu-3 in infected diabetic foot ulcers as of September 2026 [N2].
  • The company highlighted resistance data for Nu-3 supporting the National Action Plan on antibiotic resistance in July 2026 [N4].
  • Lakewood-Amedex provided progress updates on Nu-3 in diabetic foot ulcers during 2026, with stock price fluctuations reflecting these updates [N5].
  • The company debuted on Nasdaq under the ticker LABT in April 2026, with the stock price rising significantly following the listing [N6].
  • Healthcare stocks rallied in November 2026, with LABT shares soaring 240%, reflecting market interest in the company [N1].
  • Lakewood-Amedex advanced Nu-3 development progress, contributing to its inclusion among top biotech gainers in July 2026 [N3].
  • As of September 30, 2026, the company reported cash and cash equivalents of approximately $2.82 million and short-term investments of $0.5 million, with a current ratio of 5.22 and cash ratio of 4.94, indicating strong liquidity [S1].
  • The company reported a net loss of approximately $1.47 million and basic and diluted EPS of -$0.62 for the quarter ending September 30, 2026 [S1].
Overview

Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotherapeutics company developing Nu-3, a treatment candidate targeting infected diabetic foot ulcers. The company recently secured IRB approval to initiate a Phase 2a clinical trial for Nu-3 and has presented resistance data supporting its potential role in addressing antibiotic resistance. The company went public on Nasdaq in April 2026 under the ticker LABT. Financial disclosures as of Q3 2026 show the company maintains strong liquidity with cash and short-term investments totaling approximately $3.3 million and a current ratio of 5.22. The company reported a net loss for the quarter, reflecting ongoing clinical development expenses.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotherapeutics company focused on developing Nu-3 for infected diabetic foot ulcers. The company secured IRB approval to begin a Phase 2a study of Nu-3 and has highlighted resistance data supporting its development. As of September 30, 2026, the company reported strong liquidity with over $3.3 million in cash and short-term investments and a current ratio above 5. The company reported a net loss of approximately $1.47 million for the quarter ending September 30, 2026.

Scenarios for LABT

Bull case model:

The company has demonstrated progress in advancing Nu-3 through clinical development, including securing IRB approval for a Phase 2a study and presenting supportive resistance data. Strong liquidity provides runway for ongoing development activities. Positive market reception following its Nasdaq debut and subsequent stock rallies indicate investor interest in its therapeutic potential.

Bear case model:

Lakewood-Amedex operates in a high-risk clinical development environment with no approved products generating revenue. The company reported a net loss and relies on external financing to fund operations. The absence of detailed risk disclosures due to smaller reporting company status limits visibility into potential operational risks. Clinical trial outcomes and regulatory approvals remain uncertain, posing execution risks.

Moat:

Lakewood-Amedex's moat is primarily based on its clinical-stage biotherapeutic candidate Nu-3, which targets a significant unmet medical need in infected diabetic foot ulcers. The company's progress in clinical trials and regulatory approvals, along with resistance data supporting Nu-3's potential efficacy, contribute to its competitive positioning. However, as a smaller reporting company in early clinical development, its moat is contingent on successful clinical outcomes and regulatory milestones.

Risks overview
Risks summary
The primary risk for Lakewood-Amedex is the uncertainty inherent in clinical development and regulatory approval of its lead product candidate Nu-3, combined with financial constraints typical of early-stage biotherapeutics companies.
Risks details:

• Clinical Development Risk: Nu-3 is in early clinical stages, and its safety and efficacy have yet to be established through pivotal trials.
• Financial Risk: The company reported net losses and depends on available cash and investments to fund operations, which may require additional financing.
• Regulatory Risk: Approval and acceptance of Nu-3 depend on regulatory authorities and successful completion of clinical trials.
• Market Risk: As a smaller reporting company, Lakewood-Amedex faces market volatility and limited public information, which may impact investor perception.

FINAL FORECAST FOR LABT

Final take one line
Lakewood-Amedex Biotherapeutics Inc. shows high visibility through clinical progress on Nu-3, regulatory milestones, and strong liquidity as of late 2026.
Final take 12 to 24 month view

Business trends: Continued clinical development of Nu-3 targeting infected diabetic foot ulcers with regulatory approvals and resistance data support.
Execution milestones: Initiation and progress of Phase 2a clinical trials, Nasdaq listing, and maintenance of strong liquidity.
Key risks: Clinical trial outcomes, regulatory approval uncertainties, financial sustainability, and market volatility inherent to early-stage biotherapeutics.

Valye AI Visibility Research Score

Moderate visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

57
LLM visibility overview
LLM Visibility known facts
  • Lakewood-Amedex Biotherapeutics Inc. is a biotherapeutics company focused on developing treatments for diabetic foot ulcers and related infections.
  • The company is developing a lead product candidate named Nu-3, which is in clinical development for infected diabetic foot ulcers.
  • Lakewood-Amedex secured Institutional Review Board (IRB) approval to begin a Phase 2a clinical study of Nu-3 in infected diabetic foot ulcers as of September 2026.
  • The company has highlighted resistance data for Nu-3 in support of the National Action Plan on antibiotic resistance.
  • Lakewood-Amedex debuted on Nasdaq under the ticker LABT in April 2026.
  • The company provided progress updates on Nu-3 in diabetic foot ulcers during 2026, with stock price movements reflecting these developments.
  • As of September 30, 2026, the company reported cash and cash equivalents of approximately $2.82 million and short-term investments of $0.5 million, totaling about $3.32 million in liquid assets.
  • Current assets as of September 30, 2026, were approximately $3.51 million, with current liabilities of about $0.67 million, resulting in a current ratio of 5.22 and a cash ratio of 4.94, indicating strong liquidity.
  • The company reported a net loss of approximately $1.47 million for the quarter ending September 30, 2026, with basic and diluted earnings per share of -$0.62.
  • Lakewood-Amedex is classified as a smaller reporting company and is not required to provide detailed risk factors in its SEC filings.
Sources
Sources - Context summary

Generated 2026-11-17

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-11-16 | 10-Q
Sources - News headlines
  • N1 | 2026-11-05 | www.nasdaq.com | Healthcare Stocks Rally: LABT Soars 240%, ADMA 29%, WRBY 27%, CCLD 20% | https://www.nasdaq.com/articles/healthcare-stocks-rally-labt-soars-240-adma-29-wrby-27-ccld-20
  • N2 | 2026-09-21 | www.nasdaq.com | Lakewood-Amedex Secures IRB Approval To Begin Nu-3 Phase 2a Study In Infected Diabetic Foot Ulcer | https://www.nasdaq.com/articles/lakewood-amedex-secures-irb-approval-begin-nu-3-phase-2a-study-infected-diabetic-foot
  • N3 | 2026-07-23 | www.nasdaq.com | Top Biotech Gainers: ZCMD Surges 190%, LABT Advances On Nu-3 Progress, ARWR Hits The Targets | https://www.nasdaq.com/articles/top-biotech-gainers-zcmd-surges-190-labt-advances-nu-3-progress-arwr-hits-targets
  • N4 | 2026-07-22 | www.nasdaq.com | Lakewood-Amedex Highlights Nu-3 Resistance Data In Support Of National Action Plan; Stock Up | https://www.nasdaq.com/articles/lakewood-amedex-highlights-nu-3-resistance-data-support-national-action-plan-stock
  • N5 | 2026-05-18 | www.nasdaq.com | Lakewood-Amedex Provides Progress Update Of Nu-3 In Diabetic Foot Ulcers; Stock Down | https://www.nasdaq.com/articles/lakewood-amedex-provides-progress-update-nu-3-diabetic-foot-ulcers-stock-down
  • N6 | 2026-04-24 | www.nasdaq.com | Lakewood-Amedex Debuts On Nasdaq Under LABT; Stock Soar | https://www.nasdaq.com/articles/lakewood-amedex-debuts-nasdaq-under-labt-stock-soar
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine